TrialsgrambetaRCTs are beautiful

Tuberculosis

4-month regimen for drug-susceptible TB (Study 31) and 6-month BPaL/BPaLM for MDR-TB (ZeNix, TB-PRACTECAL).

  • 2022TB-PRACTECAL Core⁠MDR-TBIn 552 patients with rifampicin-resistant tuberculosis, a 24-week regimen of bedaquiline, pretomanid, linezolid and moxifloxacin improved favourable outcome at 72 weeks compared with the 9–20-month standard of care.11% vs 48%Read →
  • 2022ZeNix⁠MDR/XDR-TBIn 181 patients with MDR or XDR tuberculosis, BPaL with linezolid 600 mg for 26 weeks preserved favourable outcome while reducing toxicity compared with linezolid 1200 mg for 26 weeks.Read →
  • 2021Study 31 / A5349⁠Drug-susceptible TBIn 2,516 patients with drug-susceptible pulmonary tuberculosis, a 4-month regimen of high-dose rifapentine plus moxifloxacin was non-inferior to the standard 6-month regimen for TB-free survival.84% vs 85%Read →